TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04474405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18
Description: IV injection, 370 MBq (10 mCi), single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18
Description: IV injection, 370 MBq (10 mCi), single dose

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain PET Scan
Description: positron emission tomography (PET) scan of the brain starting immediately after administration (60 minute dynamic imaging plus 4 frames x 5 minutes at approximately 80 minutes post-dose).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Brain PET Scan
Description: positron emission tomography (PET) scan of the brain starting immediately after administration (60 minute dynamic imaging plus 4 frames x 5 minutes at approximately 80 minutes post-dose).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Whole body PET scan
Description: positron emission tomography (PET) scan of the body from the vertex of the head to the thighs starting immediately following injection and repeated over 6 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Florbetapir F 18
Description: IV injection, 370 MBq (10 mCi), single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Florbetapir F 18
Description: IV injection, 370 MBq (10 mCi), single dose

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain MRI
Description: Volume-based T1-weighted Magnetic Resonance Imaging (MRI) of the brain

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Brain MRI
Description: Volume-based T1-weighted Magnetic Resonance Imaging (MRI) of the brain
Study: NCT01473173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40mg
Study: NCT02369822

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: those who are 2-3 years will receive 400 mg/day, 4-8 years will receive 500 mg/day, those who are 9-13 years will receive 1000 mg/day, and from 14-16 years will receive 1500 mg/day
Study: NCT03442530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ToPIC
Description: Expanded tobacco cessation counseling for pregnant women.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco Treatment As Usual (TTAU)
Description: Standard of care tobacco cessation counseling for pregnant women
Study: NCT03261167

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin A (GSK1358820)
Description: GSK1358820 is sterile, purified type A botulinum neurotoxin complex. GSK1358820 injection will contain botulinum toxin A (100 units), sodium chloride (0.9 milligrams \[mg\]), and human serum albumin (0.5 mg). It will be available with doses of 400 units and 240 units.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (GSK1358820)
Description: GSK1358820 is sterile, purified type A botulinum neurotoxin complex. GSK1358820 injection will contain botulinum toxin A (100 units), sodium chloride (0.9 milligrams \[mg\]), and human serum albumin (0.5 mg). It will be available with doses of 400 units and 240 units.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (GSK1358820)
Description: GSK1358820 is sterile, purified type A botulinum neurotoxin complex. GSK1358820 injection will contain botulinum toxin A (100 units), sodium chloride (0.9 milligrams \[mg\]), and human serum albumin (0.5 mg). It will be available with doses of 400 units and 240 units.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo injection will contain sodium chloride (0.9 mg).
Study: NCT01439451

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: perturbation training
Description: The experimental and control groups will participate in 3 month training program twice a week 20 minutes each training session

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: perturbation training
Description: The experimental and control groups will participate in 3 month training program twice a week 20 minutes each training session
Study: NCT04439669

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham nrTMS and open phase
Description: Navigated repetitive TMS treatment (10 sessions during a three-week period) randomized to sham. In the following open phase stimulation the treatment targets are the right S2-contralateral M1-left S2.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active nrTMS and open phase
Description: Navigated repetitive TMS treatment (10 sessions during a three-week period) randomized to S2. In the following open phase stimulation the treatment targets are contralateral M1 and left S2. If the patient benefited from active S2 stimulation, but the treatment effect faded in follow-up, the open phase stimulation starts with right S2.
Study: NCT03530540

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-intensity extracorporeal shockwave therapy
Description: Active shockwaves

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo LI-ESWT
Description: Placebo shockwaves

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Penile pump
Description: both groups will be treated with a penile pump

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Penile pump
Description: both groups will be treated with a penile pump
Study: NCT00465738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kD), free from complexing proteins)
Description: active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins; powder for solution for injection; Mode of administration: intramuscular injection; The content of the vial was dissolved in 2.0 or 5.0 mL of sterile sodium chloride \[NaCl\] 0.9% solution without preservatives. Dilution with 2.0 or 5.0 mL resulted in a dose of 50 or 20 units per 1.0 mL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kD), free from complexing proteins)
Description: active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins; powder for solution for injection; Mode of administration: intramuscular injection; The content of the vial was dissolved in 2.0 or 5.0 mL of sterile sodium chloride \[NaCl\] 0.9% solution without preservatives. Dilution with 2.0 or 5.0 mL resulted in a dose of 50 or 20 units per 1.0 mL.
Study: NCT00820040

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acellular porcine dermal collagen mesh
Description: porcine mesh for hernia repair/ abdominal wall reconstruction
Study: NCT02058381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpelisib (BYL719)
Description: BYL 719 350 mg will be administered orally once daily on a continuous dosing schedule starting on day 1 (Group 1 only).
Study: NCT04935554

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Person centred care
Description: physical activity, nutrition, motivation, health competence, psychosocial.
Study: NCT00835614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefprozil for oral suspension 250 mg/5 mL
Description: 1 x 250 mg/5 mL, single-dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CEFZIL® for Oral Suspension 250 mg/5mL
Description: 1 x 250 mg/5 mL, single-dose fasting
Study: NCT02058381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buparlisib (BKM120)
Description: BKM120 100 mg will be administered orally once daily on a continuous dosing schedule starting on day 1 (Group 2 only)
Study: NCT03411070

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implanted Medical Device
Description: Undergo SCOUT reflector placement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study: NCT04557345

Intervention type: DIAGNOSTIC_TEST
Intervention: Two-dimensional transthoracic echocardiogram
Description: With prior informed consent, a two-dimensional transthoracic echocardiogram will be obtained by an echocardiographer certified by the Mexican Council of Cardiology (CMC) with a Phillips EPIC 7 echocardiography, 2D Arrary 3D Convex (1-6 Mhz) transducer.

Intervention type: DIAGNOSTIC_TEST
Intervention: Two-dimensional transthoracic echocardiogram
Description: With prior informed consent, a two-dimensional transthoracic echocardiogram will be obtained by an echocardiographer certified by the Mexican Council of Cardiology (CMC) with a Phillips EPIC 7 echocardiography, 2D Arrary 3D Convex (1-6 Mhz) transducer.

Intervention type: DIAGNOSTIC_TEST
Intervention: Two-dimensional transthoracic echocardiogram
Description: With prior informed consent, a two-dimensional transthoracic echocardiogram will be obtained by an echocardiographer certified by the Mexican Council of Cardiology (CMC) with a Phillips EPIC 7 echocardiography, 2D Arrary 3D Convex (1-6 Mhz) transducer.

Intervention type: DIAGNOSTIC_TEST
Intervention: Two-dimensional transthoracic echocardiogram
Description: With prior informed consent, a two-dimensional transthoracic echocardiogram will be obtained by an echocardiographer certified by the Mexican Council of Cardiology (CMC) with a Phillips EPIC 7 echocardiography, 2D Arrary 3D Convex (1-6 Mhz) transducer.
Study: NCT01370954

Intervention type: OTHER
Intervention: CerefolinNAC®
Description: CerefolinNAC® is an orally-administered medical food, and each caplet contains 2 mg Methylcobalamin, 600 mg N-acetylcysteine, and 6 mg of L-methylfolate Calcium (as Metafolin®), which is the primary biologically active and immediately bioavailable form of folate. Dosage will be 1 caplet QD.
Study: NCT02856737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eye masks and earplugs
Description: Materials similar to those offered on long commercial flights
Study: NCT03269006

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inesfly Paint
Description: Inesfly 5AIGRNG TM paint contain Alphacypermethrin 0.7%; D-Allethin 1.0% and Pyriproxyphen (0.063%).~Others intervention such as IRS, ITN and IDWLcontain Delthamethrin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IDWL (1m)
Description: Install durable wall lining up to one meter from the floor of the intervention room containing deltamethrin to kill immature stage and as well as adult sand flies

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ITN (KO-Tab 123)
Description: Impregnation of existing bed net by the insecticide tablet, K-O Tab 1-2-3 containing deltamethrin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRS (Delthamethrin)
Description: Indoor residual spraying with Delthamethrin in the living rooms
Study: NCT02400736

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Description: Individual Placement and Support (IPS) is the evidenced based model of supported employment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual Vocational Rehabilitation/Transitional Work (TUA-VR)
Description: Vocational Rehabilitation Treatment as Usual includes pre-vocational counseling, Community Based Supported Employment, or most commonly Transitional Work assignments (TW).
Study: NCT01078428

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Topical silicone gel
Description: Topical silicone gel will be applied to the scar twice daily for a period of 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vaseline
Description: Topical petrolatum gel will be applied to the scar twice daily for a period of 8 weeks
Study: NCT02955927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.01% atropine eye drops

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ortho-k

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ortho-k
Study: NCT02765893

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Foley
Description: Patients will have Foley catheter removed 6 hours post-op.
Study: NCT02542345

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Study: NCT04764604

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acapella Choice
Description: 3 minutes of exercise consisting of blowing through the device (on setting '5') and phonating at the same time.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acapella Choice
Description: 3 minutes of exercise consisting of blowing through the device (on setting '5') and phonating at the same time.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acapella Choice
Description: 3 minutes of exercise consisting of blowing through the device (on setting '5') and phonating at the same time.
Study: NCT05634564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200mg administered intravenously on Days 1 of every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 administered intravenously on Days 1 \& 8 of every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Gemcitabine 125 mg/m\^2 administered intravenously on Days 1 \& 8 of every 3 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy with simultaneous integrated boost
Description: Radiotherapy plan: Planning gross tumor volume (PGTV) 5Gy\*10 fractions, Planning target volume (PTV) 3Gy\*10 fractions.
Study: NCT03548428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200mg IV every 3 weeks for 4 months
Study: NCT04764604

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tube-in-water
Description: 3 minutes of exercise consisting of blowing through a silicone tube (10mm internal diameter) submerged in 5 cm of water whilst phonating at the same time.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tube-in-water
Description: 3 minutes of exercise consisting of blowing through a silicone tube (10mm internal diameter) submerged in 5 cm of water whilst phonating at the same time.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tube-in-water
Description: 3 minutes of exercise consisting of blowing through a silicone tube (10mm internal diameter) submerged in 5 cm of water whilst phonating at the same time.
Study: NCT01996540

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interventional arm: Early best palliative care
Description: Patients will receive standard oncologic care and will be assigned to early systematic best palliative care. They will meet a member of the palliative care team within 2 weeks after enrolment. Thereafter, they shall be visited by a palliative care team member every 2 weeks until death.
Study: NCT01305343

Intervention type: PROCEDURE
Intervention: Routinely performed surgical correction of spinal deformity
Description: Routinely performed surgical correction of spinal deformity
Study: NCT03589053

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Limb remote ischemic conditioning
Description: The LRIC treatment consisted of 5 cycles of bilateral upper limb ischemia for 5 minutes followed by reperfusion for another 5 minutes performed twice a day for a total of 90 consecutive days.The procedure was performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mmHg during the ischemic period and deflated during the reperfusion.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: Participants in the control group receive both sham LRIC and standard clinical therapy.
Study: NCT00999570

Intervention type: OTHER
Intervention: Specialty training for knee surgeons
Study: NCT03367585

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Physical exercise + Vitamin D3
Description: Strength exercise + Supplementation of vitamin D3 50,000 IU / week

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physical exercise
Description: Strength exercise
Study: NCT04119336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given intravenously once per cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Given orally on days 1, 8, 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given orally on days 1, 8, 15, 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given intravenously on days 1, 8, 15.
Study: NCT03548428

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: 3 to 5 fractions depending on tumor size
Study: NCT01263379

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LZRSE-Col7A1 Engineered Autologous Epidermal Sheets
Description: This trial will create a graft, which we call LEAES, of the patient's own skin that has been genetically engineered in our lab to express this missing protein.
Study: NCT03688737

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low level laser
Description: LLLT with wavelength (λ) of (600 nm to 700nm), The laser will be held 1 cm away from the surface of the target tissue, the irradiated area is 0,5 cm2.The area of impact is the surgical wound zone and the neighboring 0,5-1,0 cm of the adjacent oral mucosa for 1min and 22sec, at day of surgery, 1st day and 3rd day and come for follow up visits at 5th day ,2 weeks, month and 3 months postoperative

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo like device as it like low level laser device shape but with no effect to blind the intervention
Study: NCT02347007

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Almond
Description: Participants will be randomized to consume approximately 17.5% of their estimated energy requirements from almonds daily for 24 weeks. Prescribed energy requirements will be determined for each participant individually using the Mifflin St Jeor Equation equation with an activity factor of 1.3. Participants will be asked to consume half of their daily almond supplement as a mid-afternoon snack and the rest at a meal of their choice.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cereal Bar
Description: Participants will be randomized to consume approximately 17.5% of their estimated energy requirements from cereal bars daily for 24 weeks. Prescribed energy requirements will be determined for each participant individually using the Mifflin St Jeor Equation equation with an activity factor of 1.3. Participants will be asked to consume half of their daily cereal bar supplement as a mid-afternoon snack and the rest at a meal of their choice.
Study: NCT02126202

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary angiography and revascularization if feasible
Description: Coronary angiography and revascularization with PCI or CABG (coronary artery bypass grafting) if feasible
Study: NCT03521336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Mesenchymal Stem Cells
Description: Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline，Sham operation
Study: NCT03483090

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Swisse High Strength Deep Sea Krill Oil
Description: Krill oil is sourced sustainably from the Southern Ocean and is extracted from the Antarctic Krill, the most abundant marine biomass. Krill oil is a source of omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for the maintenance of good health. Omega-3, EPA and DHA are also found in phospholipid form which are much easier absorbed than triglyceride form of omega-3 which is found in fish oil. Omega-3 supports cardiovascular health, brain health and eye health. Preliminary research suggests krill oil can provide temporary relief from symptoms of mild arthritis, help reduce joint inflammation and increase joint mobility.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No therapeutic effect
Study: NCT03548428

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SBRT
Description: 3 to 5 fractions depending on tumor size
Study: NCT03008512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genexol-PM
Study: NCT02124798

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Belimumab autoinjector
Description: Single use, disposable autoinjector assembled with the prefilled syringe containing the drug product belimumab with unit dose strength of 200mg/mL and 1 mL will be given as a once weekly SC dose
Study: NCT01845389

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural (B. Braun)
Description: 20-gauge epidural catheter threaded cephalad through an 18 gauge needle identified by the loss of resistance method to air.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal (Wiley Spinal Catheter)
Description: The Wiley Spinal® is an innovative Flexible Cannula over Needle designed for convenient intrathecal access. After dural puncture is achieved, an immediate dural seal is created. The flexible cannula is advanced off the needle ensuring cephalad delivery of medication.
Study: NCT03907423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin10 mg tablet
Description: Diabetic patients treated with Rosuvastatin 10mg/day plus Glimepiride 1-8mg/day and Metformin 500-2550 mg/day oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Diabetic patients treated with Glimepiride 1-8mg/day and Metformin 500-2550 mg/day oral
Study: NCT05129202

Intervention type: DRUG
Intervention: immune therapy
Description: The patient receives immunotherapy
Study: NCT00882765

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: genistein
Description: Given orally
Study: NCT03520569

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: we are using it to block insulin secretion from the pancreas

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: we are using it to block insulin secretion from the pancreas

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: we are using it to block insulin secretion from the pancreas

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: we are using it to block insulin secretion from the pancreas
Study: NCT00446212

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: target controlled infusion of propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desflurane
Description: Anaesthetic maintenance with desflurane